← Back to Patent Explorer
US6869974B1 Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical compounds

Assignee: Nicox SA
•
Filing: 2000-04-11
•
Granted: 2005-03-22
•
Expires: 2020-04-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds or their salts having general formulas (I) and (II): wherein s is an integer equal to 1 or 2, A is the radical of a drug that satisfies certain pharmacological tests, C and C 1 are bivalent radicals, and precursors of the radicals B and B 1 satisfy certain pharmacological tests.

Inventors

  • 👤 Piero del Soldato

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 12:23
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/12; C07D235/00; C07D235/02; C07D235/04; C07D235/24; C07D235/28; A; A61; A61P; A61P39/00; A61P39/06; A61P43/00; C07C; C07C203/00; C07C203/02; C07C203/04; C07C219/00; C07C219/02; C07C219/18; C07C229/00; C07C229/52; C07C229/54; C07C229/64; C07C237/00; C07C237/48; C07C327/00; C07C327/20; C07C327/32; C07C327/34; C07D209/00; C07D209/02; C07D209/04; C07D209/10; C07D209/18; C07D219/00; C07D219/04; C07D219/08; C07D219/10; C07D233/00; C07D233/54; C07D233/64; C07D295/00; C07D295/04; C07D295/08; C07D295/084; C07D295/088; C07D401/14; C07D407/00; C07D407/02; C07D407/04; C07D417/00; C07D417/02; C07D417/12; C07D473/00; C07D473/02; C07D473/04; C07D473/06; C07D473/08; C07D473/18; C07D495/00; C07D495/02; C07D495/04; C07D499/00; C07D499/21; C07D499/44; C07D499/48; C07D499/58; C07D499/64; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/3804; C07F9/3839; C07F9/3873; C07C2601/00; C07C2601/12; C07C2601/14; C07C2603/00; C07C2603/02; C07C2603/40; C07C2603/42; C07C2603/44; C07C2603/46

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 329 words
A compound or its salt having the following general formula (I): A—B—C—N(O) 2 (I) wherein: A=R—T 1 —, wherein R is the radical of the drug, as defined hereunder, having the formula R—T 1 —Z or R—T 1 —OZ in which Z is H or C 1 -C 5 alkyl, selected from the following classes: anti-inflammatory drugs: acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium salt, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, naproxen, niflumic acid, olsalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, tolmetin and zomepirac; bronchodilators drugs: albuterol, carbuterol, clenbuterol, diphylline, etofylline, fenoterol, metaproterenol, pirbuterol, salmeterol and terbutaline; expectorant drugs: ambroxol, bromexine and guaiacol; antitumoral drugs: anthramycin, daunorubicin, doxorubicin and epirubicin; antibiotics drugs: amoxicillin, ampicillin, aztreonam, biapenem, carbenecillin, cefaclor, cefadroxil, cefamandole, cefatrizine, cefoxitin, dicloxacillin, imipenem, meclocycline, methacycline, moxalactam, panipenem, bacampicillin, apicycline, clomocycline and oxytetracycline; bone resorption inhibitors: alendronic acid, etidronic acid and pamidronic acid; antidementia drugs: tacrine; T 1 =(CO), O, S, or NR 1C , wherein R 1C is H, C 1 -C 5 alkyl, or a free valence; B=—T B —X 2 —T BI wherein T B and T BI are equal or different, T B is (CO) when T 1 is (CO), O, S, or NR 1C , wherein R 1C is as above defined, T B is O when T 1 is (CO), TBI is (CO) or O; X 2 is a bivalent bridging group such as the corresponding precursor of B, having the formula Z′—T B —X 2 T BI —Z″ in which Z′, Z″ are independently H or OH, is selected from the following compounds: Hydroxyacids: ferulic acid (DII), caffeic acid (DV), hydro caffeic acid (DVI), p-coumaric acid (DVII): C is the bivalent —T C —Y— radical, wherein T C is (CO) when T BI is O, T C is O when T BI is (CO); Y is a linear or branched (C 1 -C 20 )-alkylenoxy group
Claim 2
Dependent Claim 329 words
A compound or its salt having the following general formula (I): A—B—C—N(O) 2 (I) wherein: A=R—T 1 —, wherein R is the radical of the drug, as defined hereunder, having the formula R—T 1 —Z or R—T 1 —OZ in which Z is H or C 1 -C 5 alkyl, selected from the following classes: anti-inflammatory drugs: acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium salt, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, naproxen, niflumic acid, olsalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, tolmetin and zomepirac; bronchodilators drugs: albuterol, carbuterol, clenbuterol, diphylline, etofylline, fenoterol, metaproterenol, pirbuterol, salmeterol and terbutaline; expectorant drugs: ambroxol, bromexine and guaiacol; antitumoral drugs: anthramycin, daunorubicin, doxorubicin and epirubicin; antibiotics drugs: amoxicillin, ampicillin, aztreonam, biapenem, carbenecillin, cefaclor, cefadroxil, cefamandole, cefatrizine, cefoxitin, dicloxacillin, imipenem, meclocycline, methacycline, moxalactam, panipenem, bacampicillin, apicycline, clomocycline and oxytetracycline; bone resorption inhibitors: alendronic acid, etidronic acid and pamidronic acid; antidementia drugs: tacrine; T 1 =(CO), O, S, or NR 1C , wherein R 1C is H, C 1 -C 5 alkyl, or a free valence; B=—T B —X 2 —T BI wherein T B and T BI are equal or different, T B is (CO) when T 1 is (CO), O, S, or NR 1C , wherein R 1C is as above defined, T B is O when T 1 is (CO), TBI is (CO) or O; X 2 is a bivalent bridging group such as the corresponding precursor of B, having the formula Z′—T B —X 2 T BI —Z″ in which Z′, Z″ are independently H or OH, is selected from the following compounds: Hydroxyacids: ferulic acid (DII), caffeic acid (DV), hydro caffeic acid (DVI), p-coumaric acid (DVII): C is the bivalent —T C —Y— radical, wherein T C is (CO) when T BI is O, T C is O when T BI is (CO); Y is a linear or branched (C 1 -C 20 )-alkylenoxy group
Claim 3
Dependent Claim 22 words
The compound or salt according to claim 1 , wherein Y is a linear or branched (C 1 -C 6 )-alkylenoxy group.
Claim 4
Dependent Claim 20 words
The compound or salt according to claim 1 , wherein the bivalent bridging group X 2 is ferulic acid (DII).
Claim 5
Dependent Claim 22 words
The compound or salt according to claim 3 , wherein Y is a linear or branched (C 1 -C 6 )-alkylenoxy group.
Claim 6
Dependent Claim 19 words
A drug comprising the compound or salt according to claim 1 , in combination with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim 16 words
A pharmaceutical formulation containing the compound or salt according to claim 1 as an active component.
Claim 8
Dependent Claim 31 words
A method for treating oxidative stress dysfunction, said method comprising administering a therapeutically effective amount of the compound or salt according to claim 1 , to a patient in need thereof.

References Cited (Backward Citations)

EP0012866A1 Cited
WO1994012463A1 Cited
WO1995009831A1 Cited
WO1995030641A1 Cited
US5861426A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2008-03-21 2008-09-20 2009-03-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2012-03-21 2012-09-20 2013-03-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2016-03-21 2016-09-20 2017-03-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag